This rearrangement leads to a truncated CCDC170 protein which, when introduced into ER+ breast cancer cells, leads to increased cell motility, anchorage-independent growth, reduced endocrine sensitivity, and enhanced xenograft tumor formation. This evidence concerns the gene CCDC170 and neoplasm.